Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9829
Title: The dearth of new antibiotic development: why we should be worried and what we can do about it.
Authors: Charles, Patrick G P;Grayson, M Lindsay
Affiliation: Infectious Diseases Department, Austin Health, Heidelberg, VIC.
Issue Date: 15-Nov-2004
Citation: Medical Journal of Australia; 181(10): 549-53
Abstract: The emergence and spread of multidrug-resistant pathogens has increased substantially over the past 20 years. Over the same period, the development of new antibiotics has decreased alarmingly, with many pharmaceutical companies pulling out of antibiotic research in favour of developing "lifestyle" drugs. Reasons given for withdrawing from antibiotic development include poor "net present value" status of antibiotics, changes in regulations requiring larger drug trials and prolonged post-marketing surveillance, clinical preference for narrow-spectrum rather than broad-spectrum agents, and high new-drug purchase costs. Major improvements in infection control in Australia are needed to prevent further spread of resistant clones, buying some time to develop urgently needed new antibiotic agents. Perpetuating a culture of "pharma bashing" will simply lead to more pharmaceutical companies withdrawing from the market. A change in the health and research culture is needed to improve cooperation between public, academic and private sectors.
Internal ID Number: 15540967
URI: http://ahro.austin.org.au/austinjspui/handle/1/9829
URL: http://www.ncbi.nlm.nih.gov/pubmed/15540967
Type: Journal Article
Subjects: Anti-Bacterial Agents.therapeutic use
Drug Industry
Drug Resistance
Drug and Narcotic Control
Humans
Product Surveillance, Postmarketing
Therapeutic Equivalency
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.